Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

AbbVie Stock: Price Seems Fair for Biopharmaceutical Play

Stock MarketsOct 11, 2021 01:31PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. AbbVie Stock: Price Seems Fair for Biopharmaceutical Play

I am bullish on AbbVie (NYSE:ABBV), because its valuation multiples indicate that it trades at a discount to its fair value based on past history.

Furthermore, the dividend yield makes it an attractive income stock.

AbbVie is an American biopharmaceutical company that has a mission to discover and commercialize innovative medicines that provide solutions to the serious health issues of today.

The company’s key areas include immunology, virology, oncology, gastroenterology, women’s health, eye care, neuroscience, and products and services in its Allergan (NYSE:AGN) Aesthetics portfolio. (See Analysts’ Top Stocks on TipRanks)

Strengths

AbbVie has almost 30,000 employees across the world. The company has placed a responsibility on itself to find cures for “incurable” diseases to create a positive impact on the lives of its patients, which has led to it developing the anti-rheumatic drug Humira.

The company has been recognized by big brands like “ROBECOSAM,” “FTSE4Good,” and “World’s Best Workplaces” for its fight to create a healthier world.

The company also has a strong manufacturing capacity, and a diversified portfolio of innovative products, plus strong technological capabilities.

Recent Results

In its Q2 2021 report, AbbVie reported net global revenues of almost $14 billion, up 33.9% year-over-year from $10.4 billion in Q2 2020.

The biopharmaceutical company reported earnings of $3.11 per share for the second quarter, which met the consensus estimate, but exceeded AbbVie’s own guidance range of $3.05 to $3.09. Earnings rose 32.9% as compared to the second quarter of 2020.

Net revenue also grew 19.3%, and GAAP diluted earnings per share declined 8.7% year-over-year to $0.42 in the second quarter ended June 30, 2021.

AbbVie’s immunology segment contributed $6.1 billion to total revenue, and saw a growth of 13.8% on a comparable operational basis, and 15.1% on a reported basis.

In the United States, sales of Humira generated $4.3 billion, up 7.1% on a reported basis. However, the drug's international net revenue fell by 6% to $811 million on a reported basis owing to competition.

AbbVie has updated its GAAP EPS (diluted) guidance for Fiscal Year 2021 to $7.47 from $7.27. Moreover, the diluted EPS (adjusted) for FY2021 was increased to $12.62 from $12.52.

In June, the company also expanded its $1 billion alliance with Calico Life Sciences to discover, manufacture, and sell drugs for age-related diseases, including neurodegenerative disorders and cancer.

Valuation Metrics

AbbVie’s stock looks attractively valued right now as its EV/EBITDA ratio and price-to-normalized earnings ratio both indicate the stock is trading below its historical average.

The EV/EBITDA ratio is currently 9x compared to its five-year average of 9.9x, and the price-to-normalized earnings ratio is currently 8.5x compared to its five-year average of 10.5x.

Wall Street’s Take

From Wall Street analysts, AbbVie earns a Strong Buy analyst consensus based on 10 Buy ratings, two Hold ratings, and zero Sell ratings in the past three months. Additionally, the average AbbVie price target of $128.33 puts the upside potential at 15.6%.

Summary and Conclusions

AbbVie is a leading global pharmaceutical company whose stock price looks to be undervalued at present, based both on its valuation multiples as well as Wall Street’s overwhelming bullishness on the stock at current prices.

Furthermore, the company has a strong pipeline to replace Humira, and its attractive dividend yield means it could be a good addition to a dividend portfolio.

Disclosure: At the time of publication, Samuel Smith did not have a position in any of the securities mentioned in this article.

Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

AbbVie Stock: Price Seems Fair for Biopharmaceutical Play
 

Related Articles

Futures gain as UnitedHealth, BofA rise on results
Futures gain as UnitedHealth, BofA rise on results By Reuters - Jan 19, 2022

By Shreyashi Sanyal (Reuters) - Upbeat results from UnitedHealth and Bank of America pushed U.S. stock index futures higher on Wednesday, partially righting a wobbly start to the...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email